期刊
ACTA ONCOLOGICA
卷 61, 期 9, 页码 1036-1042出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/0284186X.2022.2114378
关键词
No treatment; untreated; urothelial carcinoma; bladder cancer; frailty
类别
This study investigated the proportion of patients with locally advanced, unresectable or metastatic urothelial carcinoma who did not receive systemic anticancer treatment, as well as the reasons for lack of treatment and overall survival. The results showed that one in three patients in the pre-immunotherapy era did not receive treatment, primarily due to poor physical condition, decreased renal function, or patient preferences. The findings emphasize the urgent need for novel and better tolerated treatment regimens for this frail patient group.
Background The proportion of patients with locally advanced, unresectable or metastatic urothelial carcinoma that do not receive systemic anticancer treatment and the reasons for lack of treatment are largely unknown. The aim of this study was to investigate the prevalence and overall survival of this patient group and reasons for omission of treatment. Material and methods This retrospective, single-center cohort study from Rigshospitalet, Denmark included patients diagnosed with locally advanced, unresectable or metastatic urothelial carcinoma during the study period from 1 January 2010 to 31 March 2016 who did not receive systemic anticancer treatment. Patients were identified through the Danish Pathology Register and the electronic medical records. Results 100 patients were included, representing 34% of all patients diagnosed with locally advanced, unresectable or metastatic urothelial carcinoma at Rigshospitalet during the study period. Lack of treatment was most often due to poor physical condition (59%), decreased renal function (15%), or patient preferences (14%). Median overall survival was 1.9 months (95% CI: 1.6-2.8 months). Conclusion One in three patients diagnosed with locally advanced, unresectable or metastatic urothelial carcinoma in the pre-immunotherapy era did not receive systemic anticancer treatment. Prompt identification of advanced disease and interventions to optimize these patients for treatment are essential. Our findings underscore the compelling need for novel, better tolerated treatment regimens in this frail patient group.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据